Latest Blog Posts Tagged "LRRK2"
September 17, 2018
MJFF scientists presented and shared ideas at the Biochemical Society's Biennial International LRRK2 Meeting.
August 10, 2018
An MJFF-funded study suggests that a drug targeting the LRRK2 genetic mutation may positively impact the broader PD population.
August 02, 2018
Denali will move its drug into trials with patients with or without a LRRK2 mutation after new research points to potential widespread use of these therapies.
July 27, 2018
New findings show that Parkinson's disease patients may benefit from therapies targeting LRRK2, even if they don't have a LRRK2 gene mutation.
May 03, 2018
Dr. Dario Alessi, a leader in many Foundation and field-wide initiatives to understand Parkinson's, is recognized for his commitment.
March 28, 2018
Findings from two studies supported by The Michael J. Fox Foundation report how Parkinson's motor symptoms progress in distinct patient populations.
January 18, 2018
This connection, published by researchers from Mount Sinai in New York City, may help better understand and treat these diseases.
January 12, 2018
Michael J. Fox Foundation-funded researchers have created exquisitely sensitive antibodies that may help test therapies against a top Parkinson's drug target.
December 21, 2017
Denali Therapeutics announced its first-in-human LRRK2 inhibitor is safe and lowers LRRK2 protein activity in humans' body cells, meaningful milestones for this potentially disease-modifying therapy.
August 15, 2017
The launch of key Parkinson's protein LRRK2 into space inspires a Patient Council member's actions in pursuit of a cure and his daughter's curiosity around research.